Watch IMCR. Know when insiders buy.
One email the day a filing lands. Free.
IMCR
Immunocore Holdings plc
32.30
+0.71 +2.25%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
53
WATCH · shorts 53
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -2.47%REV TTM $430.8M +21.0%NET INCOME −$18.1MNET CASH $46.2M52W 27.79 – 40.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $115.9M | +18.3% | 99.1% | −$3M | −$808K | — | -0.02 | $15.9M | $786K | $15.1M | Aug 6 |
| Q1 2026 · Mar 31 | $106.7M | +13.6% | 99.6% | $7.3M | $13M | +158.2% | 0.25 | −$13.8M | $1.8M | −$15.6M | Aug 6 |
| Q4 2025 · Dec 31derived | $104.5M | +24.3% | 97.4% | −$19.7M | −$30.1M | — | -0.60 | −$32.7M | $2.9M | −$35.5M | Feb 25 |
| Q3 2025 · Sep 30 | $103.7M | +29.2% | 99.5% | −$7.2M | −$177K | −102.0% | 0.00 | −$4.5M | $748K | −$5.2M | Nov 6 |
| Q2 2025 · Jun 30 | $98M | +29.9% | 98.9% | −$14.9M | −$10.3M | — | -0.20 | $26M | $414K | $25.6M | Aug 6 |
| Q1 2025 · Mar 31 | $93.9M | +33.2% | 99.1% | −$3.6M | $5M | — | 0.10 | $435K | $298K | $137K | Aug 6 |
| Q4 2024 · Dec 31derived | $84.1M | +19.8% | 99.6% | −$19.5M | −$23.8M | — | -0.47 | −$14M | $3.6M | −$17.5M | Feb 25 |
| Q3 2024 · Sep 30 | $80.2M | +23.7% | 99.4% | −$8.5M | $8.7M | +864.2% | 0.17 | $21.1M | $828K | $20.3M | Nov 6 |
| Q2 2024 · Jun 30 | $75.4M | — | 97.7% | −$16M | −$11.6M | — | -0.23 | $23.5M | $331K | $23.1M | Nov 6 |
| Q1 2024 · Mar 31 | $70.5M | — | 99.7% | −$26.5M | −$24.4M | — | -0.49 | −$4.6M | $430K | −$5M | Nov 6 |
| Q4 2023 · Dec 31derived | $70.2M | — | 99.7% | −$17.1M | −$19.7M | — | -0.40 | −$17.7M | $817K | −$18.6M | Feb 25 |
| Q3 2023 · Sep 30 | $64.8M | — | 99.6% | −$14.1M | $906K | — | 0.02 | $10.1M | $212K | $9.9M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $400M | 98.7% | −$45.4M | −$35.5M | -8.9% | -0.71 | −$10.7M | $4.3M | −$15.1M | — | — |
| FY2024 · to Dec 31 | $310.2M | 99.1% | −$70.5M | −$51.1M | -16.5% | -1.02 | $26.1M | $5.2M | $20.9M | — | — |
| FY2023 · to Dec 31 | $249.4M | 99.6% | −$59.6M | −$55.3M | -22.2% | -1.13 | $2.9M | $5.4M | −$2.5M | — | — |
| FY2022 · to Dec 31 | $174.4M | 99.4% | −$51.7M | −$52.5M | -30.1% | -1.15 | −$49.2M | $2.2M | −$51.4M | — | — |
| FY2021 · to Dec 31 | $36.5M | 100.0% | −$174.6M | −$180M | -493.4% | -4.24 | −$143.1M | $1.4M | −$144.5M | — | — |
Every number comes from Immunocore Holdings plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.